Last $2.58 USD
Change Today -0.02 / -0.77%
Volume 678.3K
RIGL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/2/14 All times are local (Market data is delayed by at least 15 minutes).

Audit Committee* - rigel pharmaceuticals inc (RIGL)

Name (Connections)Board RelationshipsTitleKey Developments
Stephen Sherwin M.D. 168 RelationshipsDirector, Chairman of Finance Committee, Member of Audit Committee and Member of Nominating & Corporate Governance Committee 
Bradford Goodwin 16 RelationshipsDirector and Chairman of Audit Committee 

Compensation Committee* - rigel pharmaceuticals inc (RIGL)

Name (Connections)Board RelationshipsTitle
Gary Lyons 32 RelationshipsLead Independent Director, Chairman of Compensation Committee and Member of Finance Committee
Walter Moos Ph.D. 17 RelationshipsDirector, Chairman of Nominating & Corporate Governance Committee and Member of Compensation Committee
Peter Ringrose M.A, Ph.D. 64 RelationshipsDirector, Member of Nominating & Corporate Governance Committee and Member of Compensation Committee
RIGL Compensation vs. Industry
695.1K
365.4K
Chief Executive Officer
441.3K
270.5K
Chief Financial Officer
551.7K
351.9K
Chief Operating Officer
Share price activity for RIGEL PHARMACEUTICALS INC (RIGL)
52 Week Price Performance
RIGL
Industry Average

Nominating Committee* - rigel pharmaceuticals inc (RIGL)

Name (Connections)Board RelationshipsTitleKey Developments
Walter Moos Ph.D. 17 RelationshipsDirector, Chairman of Nominating & Corporate Governance Committee and Member of Compensation CommitteeRigel Pharmaceuticals, Inc. Announces Resignation of Hollings C. Renton as Member of the Board of Directors, Effective March 30, 2014
03/21/14
Stephen Sherwin M.D. 168 RelationshipsDirector, Chairman of Finance Committee, Member of Audit Committee and Member of Nominating & Corporate Governance CommitteeRigel Pharmaceuticals, Inc. Announces Senior Management Promotions
06/1/10
Peter Ringrose M.A, Ph.D. 64 RelationshipsDirector, Member of Nominating & Corporate Governance Committee and Member of Compensation CommitteeDaniel Magilavy Joins Rigel as Vice President of Clinical Research
02/26/08

Corporate Governance Committee* - rigel pharmaceuticals inc (RIGL)

Name (Connections)Board RelationshipsTitle
Walter Moos Ph.D. 17 RelationshipsLead Independent Director, Chairman of Compensation Committee and Member of Finance Committee
Peter Ringrose M.A, Ph.D. 64 RelationshipsDirector, Chairman of Nominating & Corporate Governance Committee and Member of Compensation Committee
Stephen Sherwin M.D. 168 RelationshipsDirector, Member of Nominating & Corporate Governance Committee and Member of Compensation Committee
RIGL and Competitor
Insiders vs. External
Board
29%
71%
Rigel Pharmaceuticals, Inc.
6%
94%
ArQule Inc.
9%
91%
Array BioPharma, Inc.
15%
85%
CTI BioPharma Corp.
16%
84%
Progenics Pharmaceuticals, Inc.
40%
60%
CrystalGenomics, Inc.
Insiders
External Board Members

Finance Committee* - rigel pharmaceuticals inc (RIGL)

Name(Connections)Board RelationshipsTitle
James Gower 6 RelationshipsChairman, Chief Executive Officer and Member of Finance Committee
Gary Lyons 32 RelationshipsLead Independent Director, Chairman of Compensation Committee and Member of Finance Committee
Stephen Sherwin M.D. 168 RelationshipsDirector, Chairman of Finance Committee, Member of Audit Committee and Member of Nominating & Corporate Governance Committee
Debt To Total Capitalization--
It is important for the finance committee to know when to issue debt or equity.
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RIGL:US $2.58 USD -0.02

RIGL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.29 USD -0.03
Array BioPharma Inc $3.85 USD -0.10
CrystalGenomics Inc 14,350 KRW -250.00
CTI BioPharma Corp $2.48 USD -0.08
Progenics Pharmaceuticals Inc $5.56 USD +0.05
View Industry Companies
 

Industry Analysis

RIGL

Industry Average

Valuation RIGL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 39.6x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RIGEL PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.